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Carcinoma of unknown primary site remains a common clinical diagnosis, accounting for between 5 and 10% of all cancer
patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown
primary site, resulting in response rates of 0–48%. We present the results of a single centre phase II study of the use of the
combination of mitomycin C (7 mg m
72 on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m
72 on day 1) and continuous
infusion 5-ﬂuorouracil (300 mg m
72 daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary
site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Inﬁrmary
between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient). Toxicity was
acceptable, with 19% grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and
vomiting. No cases of neutropenic sepsis were seen and there were no treatment-related deaths, however, six patients
developed thrombotic complications. The overall response rate was 27% (CR 3%; PR 23%). Median time to progression was
3.4 months (95% CI 1.1–5.6 months) and median overall survival was 7.7 months (95% CI 5.7–9.8 months). Survival at 1
year was 28%, and at 2 years, 10%. MCF is a tolerable regimen with comparable toxicity, response rates and survival data to
most platinum-based combination chemotherapy regimens in use for this devastating disease.
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The diagnosis of carcinoma of unknown primary site accounts for
5–10% of all new patients referred to oncology clinics (Greco and
Hainsworth, 1992). Of these, about 60% are identiﬁed on light
microscopy and immunohistochemistry as being adenocarcinomas
(Hainsworth and Greco, 1993). Adenocarcinoma of unknown
primary site (ACUP) is a diagnosis which generally carries a poor
prognosis. Historically, the median survival for this condition has
been reported as 3.1 months (Markmann, 1982), however, more
recent phase II studies of combination chemotherapy have gener-
ally resulted in median survival times of over 6 months. Certain
subgroups of patients have been identiﬁed with a more favourable
prognosis, namely patients with neuro-endocrine tumours (Lenzi et
al, 1997), women with lone axillary metastases (Ellerbroek et al,
1990) or diffuse peritoneal carcinomatosis (Strnad et al, 1989),
and men with an elevated serum prostate-speciﬁc antigen (PSA)
or with tumour that stains for PSA (Tell et al, 1985).
The most common metastatic sites in ACUP are lymph nodes,
lung, liver and bone. Intensive investigation rarely identiﬁes a
primary site, and if successful, seldom alters treatment (Stewart
et al, 1979). Therefore, only a limited search for the primary site
is generally adopted in the absence of speciﬁc symptomatology.
Tests include complete physical examination, tumour markers,
stool Haemoccult test, chest radiography and abdominopelvic CT
scan, as well as mammography in women. Further investigations,
such as chest CT scan, endoscopy and barium studies, may be
performed if the clinical scenario is suggestive of a particular
primary site.
In only 15–20% of patients with ACUP does the primary site
subsequently declare itself during life, however, post-mortem
studies can deﬁne the primary in some 70–80% of cases (Nystrom
et al, 1977). From such examinations, it can be seen that the
commonest origins for ACUP are lung and pancreas, followed by
stomach, colon and oesophagus, explaining the generally poor
prognosis of these patients.
No large randomised trials of chemotherapy vs best supportive
care have been performed, however, an analysis of the outcomes
of 222 patients with hepatic metastases from ACUP by Ayoub et
al (1998), showed that delivery of chemotherapy was associated
with improved survival (hazard ratio 0.43, P50.0001), after adjust-
ing for age and number of metastatic sites. Single agent
chemotherapy studies in patients with ACUP show response rates
for 5-ﬂuorouracil (5-FU) and cisplatin of 0–16% and 19% respec-
tively (Johnson et al, 1964; Moertel et al, 1972; Schildt et al, 1983;
Wagener et al, 1991). Numerous phase II studies have been
performed with combination chemotherapy regimens (Anderson
et al, 1983; Jadeja et al, 1983; van der Gaast et al, 1988; Becouarn
et al, 1989; Treat et al, 1989; Hainsworth et al, 1997; Warner et al,
1998; Lofts et al, 1999; Briasoulis et al, 2000; Dowell et al, 2001;
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response rates between 10 and 40%. More recently, the addition
of paclitaxel, with its broad spectrum of activity, into combination
regimens, has yielded response rates approaching 50% (Hainsworth
et al, 1997; Greco et al, 2000). One problem with comparison of
these studies is the heterogeneity of the study populations and
differing stringency with which investigators attempt to exclude
breast cancer, ovarian cancer and germ cell tumours as potential
primary sites, i.e. those tumours which are associated with better
survival and which can therefore markedly skew outcome data.
The rationale for studying MCF lies in the activity of mitomycin
C in lung and gastrointestinal (G-I) cancers, of cisplatin in lung,
breast, ovarian and upper G-I cancers, and of 5-FU in breast and
G-I cancers, thereby producing a combination with potential activ-
ity against the main primary tumour sites responsible for ACUP. In
addition, the three agents give rise to generally non-overlapping
toxicities.
MATERIALS AND METHODS
Patient selection and investigation
Patients were eligible for the study if there was a cytologically or
histologically conﬁrmed diagnosis of carcinoma of unknown
primary. Patients were required to be aged between 18 and 75,
chemo-naı ¨ve, have a WHO performance status of 42 and have
adequate haematological, renal and liver function.
All patients were evaluated clinically by medical history and
physical examination. Baseline investigations included full blood
count, serum biochemistry and tumour markers (CEA and Ca125
in women; CEA and PSA in men, plus bHCG and AFP in cases
of poorly differentiated carcinomas in males under 50 years). Plain
chest radiographs and abdominopelvic CT scans were performed,
with mammography in women. Further investigations, such as
chest CT scan, pelvic ultrasound, endoscopy, barium studies and
bone scintigraphy were performed dependent on the patient’s
symptoms or signs.
All pathology was analysed centrally. Where adenocarcinoma
was diagnosed on light microscopy, immunohistochemistry was
performed on the pathological specimen for CEA and PSA in
men, and for CEA, Ca125 and hormone receptors in women.
Where poorly differentiated tumour was diagnosed on light micro-
scopy and immunohistochemistry, appropriate stains were used to
conﬁrm carcinoma (including cytokeratins and epithelial
membrane antigen) and exclude haematological malignacies, mela-
noma, germ cell tumours and sarcoma (including common
leucocyte antigen, CD30, S-100, bHCG, AFP and vimentin).
Patients were excluded if tumour markers, radiology and/or the
clinical scenario were in keeping with primary prostatic cancer
(PSA 410 ng ml
71 and/or bone only disease in a male), ovarian
or primary peritoneal cancer (women with only peritoneal disease
and Ca125 450 U ml
71), or germ cell neoplasm (predominantly
midline poorly differentiated tumour in a male under the age of
50, with or without elevated bHCG or AFP), or if they had nodal
disease only which was localised to a single lymph node region.
Treatment schedule
The MCF regimen was delivered every 21 days for a maximum of
six cycles. Mitomycin C (7 mg m
72; maximum dose 14 mg) was
delivered on day 1 of every alternate cycle. Cisplatin (60 mg m
72
with pre- and post-hydration, frusemide and mannitol) was deliv-
ered on day 1 of each cycle. 5-FU was delivered as a continuous
infusion (300 mg m
72 day) throughout treatment, via a tunnelled
catheter and portable pump. Prophylactic warfarin (1 mg daily)
was given to reduce the incidence of line-associated thrombosis.
Prophylactic anti-emetic therapy consisted of 8 mg dexamethasone
and 8 mg ondansetron pre-treatment, and thereafter 2 mg dexa-
methasone t.d.s and 8 mg ondansetron b.d. for 3 days and was
altered as required. Chlorhexidine mouthwash was supplied to all
patients.
Prior to each cycle of therapy (whether mitomycin C was due or
not), adequate haematological function (neutrophil 51.0610
9 per
litre and platelets 5100610
9 per litre) was required, otherwise
chemotherapy was delayed (and the infusional 5-FU discontinued)
for 1 week or until the myelosuppression had resolved. Renal func-
tion was monitored by calculating creatinine clearance prior to
each cycle, to ensure a clearance of 560 ml min
71. For values below
60 ml min
71, the total dose of cisplatin per cycle was reduced to the
GFR value in mg, and below 40 ml/min, cisplatin was omitted.
In the event of oral mucositis or grade 2 diarrhoea, infusional 5-
FU was discontinued for at least 1 week, then reinstituted at a
reduced dose of 250 mg m
72 when the symptoms resolved. If still
not tolerated, the dose was reduced further to 200 mg m
72.
Toxicity
Toxicity was assessed for all cycles according to NCI Common
Toxicity Criteria version 2.0, and was recorded as the worst toxicity
experienced per patient.
Response evaluations
The outcomes measured were tumour response (evaluated accord-
ing to WHO response criteria), time to progression and overall
survival. Response was assessed at each cycle by clinical examina-
tion, tumour markers and CXR if appropriate. CT scans were
repeated after 3 and 6 cycles of chemotherapy. Although WHO
response criteria were used, it was not possible to conﬁrm
responses after 1 month because of resource limitations. Time to
progression and overall survival were deﬁned as the time from
the ﬁrst cycle of therapy to the date of documented progression
(clinical or radiological) or death, respectively.
Statistical analyses
The response rates for previous platinum- or taxane-based regimens
in carcinoma of unknown primary lie between 19 and 50% (see Table
5). Assuming a 35% response rate in a sample of 30 evaluable
patients, the 95% conﬁdence interval would be 10 to 50%.
Median time to progression and median overall survival were
estimated by the Kaplan Meier method (Kaplan and Meier,
1958) using SPSS version 9.0.
RESULTS
Thirty-one consecutive eligible patients with CUP were recruited
into the study at Aberdeen Royal Inﬁrmary between April 1997
and January 2001. The patient characteristics are listed in Table
1. None of the four patients with only nodal metastases had disease
which was localised to a single radically-treatable subsite (with
widespread retroperitoneal lymphadenopathy in three cases, and
mediastinal, axillary and cervical lymphadenopathy in the fourth).
The two patients with solely peritoneal disease were both investi-
gated by specialist gynaecological oncology surgeons, and had
normal or marginally-elevated serum Ca125 and adenocarcinomas
that did not stain positively for Ca125. In both cases, the clinical
scenario, the tumour histology and the pattern of disease found
at operation were felt to make the diagnosis of ovarian or primary
peritoneal carcinoma unlikely.
Drug delivery
A total of 136 cycles of MCF chemotherapy was delivered, with a
median of 5 cycles per patient (range 2–6). Twenty-two cycles
were delayed, most by only 1 week. The reasons for delay were
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vomiting, grade 4 constipation, grade 2 diarrhoea and unexplained
jaundice in one case each.
Dose reductions were instituted for mitomycin C in two patients
(due to neutropenia), for cisplatin in four patients (due to
impaired renal function from the start of chemotherapy in two
cases and multiple toxicities in two cases) and for 5-FU in 12
patients (for reasons of stomatitis in seven, palmar-plantar
syndrome in three, and diarrhoea and neutropenia in one case
each).
The delivered dose intensity for each drug was calculated by
averaging the mean dose received per week for the entire treatment
course for each patient, and the results are compared with the
intended dose intensities in Table 2.
Toxicity
No treatment-related deaths were observed within the study. There
were 12 emergency admissions in 11 patients. The reasons for
admission were thrombotic complications in four cases, and one
case each of urinary retention, rigors with no other evidence of
infection, grade 3 vomiting, grade 4 thrombocytopenia and grade
4 anaemia. The remaining three admissions arose as a consequence
of disease progression rather than therapy, two with bowel obstruc-
tion and one with obstructive uropathy.
All patients were assessable for toxicity and the data are
summarised in Table 3. Nineteen per cent of patients experienced
grade 3 or 4 neutropenia (none with sepsis), 16% with grade 3 or 4
thrombocytopenia and 13% with grade 3 nausea and vomiting. No
cases of haemolytic uraemic syndrome were seen.
5-FU related toxicity was common, with 48, 33 and 22% of
patients experiencing grade 1 or 2 stomatitis, diarrhoea and
palmar-plantar syndrome respectively, however, severe toxicity
was rare.
No patients developed signiﬁcant chemotherapy-related nephro-
toxicity, although the calculated creatinine clearance fell by between
10 and 20% in ﬁve patients from the start to the end of
chemotherapy. In no case did calculated renal function fall by more
than 20%.
A total of six Hickman line complications occurred in four
patients. There were three episodes of subclavian vein thrombosis,
two episodes of line infection and one pneumothorax.
Response
Thirty patients had measurable disease and were included in the
response assessment. After six cycles of MCF, eight patients had
responded to chemotherapy, one complete response (3%) and
seven partial responses (23%), giving an overall response rate of
27% (95% CI 11–42%). In total, 63% of patients progressed
during their chemotherapy. Of the 10 patients who had stable
disease after three cycles, two subsequently achieved a partial
response (both of whom had shown a minor response after three
cycles), three maintained stable disease and ﬁve had progressed
by completion of treatment. Of the eight patients who had a partial
response after three cycles, two had progressed by the end of the
sixth cycle; in view of the lack of a conﬁrmatory 1 month scan,
the initial responses of these two patients were not included in
the overall response rate.
All eight patients who achieved a response after six cycles of
chemotherapy had a histological diagnosis of adenocarcinoma (as
opposed to poorly differentiated carcinoma), six with liver involve-
ment and one each with node only and peritoneum only disease.
Table 4 summarises the response data.
Survival
Survival data were available for all 31 patients. After a median of
25 months follow-up (range 7–53 months), the survival data are
mature. Median time to progression is estimated as 3.4 months
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Table 1 Patient characteristics
Number of patients 31
Gender 18 male
13 female
Median age (range) 63 (40–72)
Performance status:
0 6 (19%)
1 20 (65%)
2 5 (16%)
Pathology:
Adeno 22 (71%)
PDA 5 (16%)
PDC 3 (10%)
Neuro-endocrine 1 (3%)
Number of metastatic sites:
1 site 15 (48%)
liver only 7 (23%)
LN only 4 (13%)
peritoneum only 2 (6%)
pleura only 1 (3%)
lung only 1 (3%)
2 sites 8 (26%)
3 or more sites 8 (26%)
Liver involvement:
yes 20 (65%)
no 11 (35%)
Prior therapy:
none 27 (87%)
palliative RT 4 (13%)
Subsequent therapy:
hormonal therapy 5 (16%)
palliative RT 6 (19%)
phase I agents 4 (13%)
repeat MCF 1 (3%)
Abbreviations; Adeno, unspeciﬁed, well or moderately differentiated adenocarcino-
mas; PDA, poorly differentiated adenocarcinoma; PDC, poorly differentiated
carcinoma; LN, lymph nodes; RT, radiotherapy.
Table 2 Comparison of intended and delivered dose intensities
Dose intensity (mg m
72 per week)
Mitomycin C Cisplatin 5-FU
Intended doses 1.17 20 2100
Delivered doses 1.03 17.2 1723
% of intended dose 88% 86% 82%
Table 3 Summary of toxicities (n=31) expressed as the worst CTC
toxicity grade on any cycle of chemotherapy (% of patients)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Anaemia 13 32 52 0 3
Leucopenia 48 23 19 6 3
Neutropenia 65 10 6 13 6
Thrombocytopenia 52 19 13 10 6
Palmar-plantar syndrome 74 6 16 3 0
Nausea 45 23 19 13 0
Vomiting 58 10 19 13 0
Stomatitis 48 29 19 3 0
Constipation 68 6 16 3 6
Diarrhoea 68 23 10 0 0
Alopecia 87 10 3 – –
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(95% CI 5.7–9.8 months (Figure 1)). Actuarial 1-year survival is
28% and 2-year survival is 10%. Meaningful multivariate analysis
is precluded by the small patient population in this study, however,
of the eight patients who had survived 1 year by the time of the
analysis, all had a performance status of 0 or 1, seven had a histo-
logical diagnosis of adenocarcinoma (the eighth being diagnosed
with a neuro-endocrine tumour) and six had disease involving
the liver. One patient had solely nodal disease.
DISCUSSION
The MCF regimen was found to be generally well tolerated in
patients with carcinoma of unknown primary, with grade 3 or 4
toxicity rates which are very similar to those reported for the same
regimen when used in gastric carcinoma (Ross et al, 1999). Twelve
patients required dose reductions of 5-FU, three of whom required
a second dose reduction, mainly for reasons of stomatitis and
palmar-plantar syndrome. This level of toxicity suggests that a daily
dose of 250 mg m
72 of 5-FU may be preferable as a starting dose.
A response rate of 27% was seen. Of the eight patients who had
stable disease with no evidence of even a minor response after three
cycles of MCF, ﬁve had progressed by the sixth cycle and only
three maintained stability, raising the suggestion that in those
patients without any demonstrable reduction in tumour size after
three cycles, MCF should be discontinued.
The 27% response rate and 7.7 month median survival observed
with MCF are broadly similar to other cisplatin-based regimens
(see Table 5), however, the addition of taxanes appears substan-
tially to improve both outcomes. The broad spectrum of activity
of the taxanes would predict their efﬁcacy in a heterogeneous
condition such as CUP and indeed, the two taxane-based phase
II studies with the highest response rates (Hainsworth et al,
1997; Briasoulis et al, 2000) resulted in median survival times of
13–14 months, almost double those of most other non-taxane
regimens. The carboplatin-paclitaxel study (Briasoulis et al, 2000)
differs from our study and many others in the characteristics of
patients included, with 23% of patients diagnosed with peritoneal
carcinomatosis (who would be expected to respond well to ‘ovarian
cancer’ chemotherapy) and with only 25% of patients recognised as
having liver metastases (compared with 65% in our study). When
the node only and peritoneal carcinomatosis subsets were removed
from the analysis, median survival dropped to 10 months, in keep-
ing with the results of a study of taxane-platinum chemotherapy in
a less highly selected group of patients (Greco et al, 2001). In the
carboplatin-paclitaxel-etoposide study (Hainsworth et al, 1997),
24% of patients had node only disease and less than 40% had liver
involvement. A randomised phase II comparison of paclitaxel, 5-
FU and leucovorin vs carboplatin and etoposide (Dowell et al,
2001) in 34 patients, 62% of whom had liver metastases, yielded
response rates of 19% in both arms, with median survival of less
than 9 months, however, the small numbers in each arm again
make interpretation difﬁcult.
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Table 4 Summary of responses (n=30) after three and six cycles of MCF
Number (per cent) Number (per cent)
Response after 3 cycles after 6 cycles
Complete response 0 (0%) 1 (3%)
Partial response 8 (27%) 7 (23%)
Stable disease 10 (33%) 3 (10%)
Progressive disease 12 (40%) 19 (63%)
Table 5 Comparison of outcomes of carcinoma of unknown primary trials
Patient Response Median 1 year 2 year
Reference Regimen number rate survival survival survival
MCF 31 27% 7.7 months 28% 10%
van der Gaast et al, 1988 FAM 22 14% 5.5 months N/A N/A
Treat et al, 1989 Me-FAM 19 37% 15 months N/A N/A
Lofts et al, 1999 Cis/F/Tamoxifen 44 27% 4 months N/A N/A
Anderson et al, 1983 VAC 20 50% 8 months N/A N/A
Jadeja et al, 1983 FACP 23 23% 5.5 months 20% N/A
Becouarn et al, 1989 FAP-Altretamine 85 21% 7 months 25% N/A
Guardiola et al, 2001 CAP 22 50% 10.7 months N/A N/A
Warner et al, 1998 Carbo-Etop 33 23% 5.6 months N/A N/A
Briasoulis et al, 2000 Carbo-Taxol 77 39% 13 months N/A N/A
Dowell et al, 2001 Taxol/5FU/LV 17 19% 8.3 months 26% N/A
Carbo/Etop 17 19% 6.4 months
Hainsworth et al, 1997 Taxol/Carbo/Etop 55 47% 13.4 months *58% N/A
Greco et al, 2000 Taxol/Carbo/Etop 71 48% 11 months 48% 20%
Greco et al, 2001 Taxol/Carbo/Etop 71 36% 10 months 42% 22%
Docetaxel/Cisplatin 26
Docetaxel/Carbo 47
A, doxorubicin (Adriamycin); C, cyclophosphamide (or cisplatin in MCF); Carbo, carboplatin; F, 5-ﬂuorouracil; LV, leucovorin; M, mitomycin C; Me, methotrexate; P or Cis,
cisplatin; V, vincristine; N/A, data not available.
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Figure 1 Kaplan–Meier curve of overall survival (n=31).
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CUP, where the majority of patients do not respond to chemother-
apy, are longer term follow-up data. In our study, 28% of patients
survived 1 year, and 10% survived 2 years. This is in keeping with
two previous cisplatin-based studies in which 1-year survival is
reported as 20–25% (Jadeja et al, 1983; Becouarn et al, 1989).
Three of the taxane-based studies describe more impressive 1-
and 2-year survival rates of 42–58% and 20–22% respectively
(Hainsworth et al, 1997; Greco et al, 2000, 2001) and indeed 3-year
survival of 14–17% is also quoted (Greco et al, 2000, 2001).
While the addition of a taxane to chemotherapy for CUP may
well be advantageous, heterogeneity in patient characteristics in
phase II studies makes this extremely difﬁcult to demonstrate
convincingly at present. This problem is exempliﬁed by the very
impressive 15 month median survival quoted for me-FAM (Treat
et al, 1989), but with only 19 patients of median age 49 years,
few of whom had liver metastases, meaningful comparison is
impossible.
The heterogeneity of these tumours continues to be the
problem, and perhaps the future for the management of cancers
of unknown primary lies in improved molecular proﬁling and
better targeted therapy.
CONCLUSION
MCF appears to be an active regimen in good performance
status patients with carcinoma of unknown primary, although
in view of the 5-FU-related toxicity observed in this study, a
dose of 250 instead of 300 mg m
72 day of 5-FU is recom-
mended. The advent of capecitabine may allow the replacement
of continuous infusion 5-FU with this oral antimetabolite in
due course, removing the potential complications associated with
Hickman lines. The role of the taxanes in this heterogeneous
disease requires evaluation in a randomised study and our future
plans include a comparison of MCF with a taxane based regi-
men.
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